An Investigation into the Surface Dose Using Eclipse Treatment Planning System and Film Dosimetry for Treatment of Breast Cancer

Nooshin  Sheykholeslami; Wrya  Parwaie; Mostafa  Farzin; Vahid  Vaezzadeh; Ghazale Geraily

doi:10.18502/fbt.v10i1.11509

Nooshin Sheykholeslami Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Wrya Parwaie Department of Laboratory Sciences, School of Allied Medical Sciences, Ilam University of Medical sciences, Ilam, Iran
Mostafa Farzin Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Vahid Vaezzadeh Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Ghazale Geraily Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

DOI: https://doi.org/10.18502/fbt.v10i1.11509

Keywords: Film Dosimetry; Surface Dose; Treatment Planning System.

Abstract

Purpose: Accurate knowledge about surface dose distribution is a critical issue in skin irradiation. This study was conducted to investigate the surface dose using the Eclipse Treatment Planning System (TPS) calculation and GAF chromic film measurement for breast cancer treatment.

Materials and Methods: An inhomogeneous chest phantom was used in the present study. Irradiations were done with a 6 MV energy beam of a linear accelerator (Varian 2100C/D). TPS calculations and film measurements were compared for surface dose estimations.

Results: The average difference between film measurements and TPS calculations was 7.1%. Surface doses were lower in TPS calculations in comparison with film measurements.

Conclusion: TPS plays a significant role in radiotherapy. However, they have many errors in measuring surface doses. Because of the inaccuracy of the majority of treatment planning systems in calculating the surface dose, the need for practical measurements is essential.